参考文献/References:
[1] Vachiery JL,Adir Y,Barbera JA,et al.Pulmonary hypertension due to left heart diseases[J]. J Am Coll Cardiol,2013,62(25 Suppl):D100-108.
[2] Galiè N, Humbert M, Vachiery JL, et al.2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J 2015,46(4):903-975.
[3] Guazzi M,Borlaug BA. Pulmonary hypertension due to left heart disease[J]. Circulation,2012,126(8):975-990.
[4] Gerges M, Gerges C, Pistritto AM,et al. Pulmonary hypertension in heart failure. Epidemiology, right ventricular function, and survival[J]. Am J Care Med, 2015,192(10):1234-1246.
[5] Hoeper MM, Bogaard HJ,Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension[J]. J Am Coll Cardiol,2013,62(25 Suppl):D42-D50.
[6] Rosenkranz S,Gibbs JSR,Wachter R, et al. Left ventricular heart failure and pulmonary hypertension[J]. Eur Heart J,2015,37(12):942-954.
[7] Miller WL, Grill DE,Borlaug BA, et al.Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction[J]. JACC Heart Fail,2013,1(4):290-299.
[8] Naeije R,Vachiery JL,Yerly P, et al. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease[J]. Eur Respir J,2012,41(1):217-223.
[9] Thenappan T,Gomberg MM.Epidemiology of pulmonary hypertension and right ventricular failure in left heart failure[J]. Curr Heart Fail Rep,2014,11(4):428-435.
[10] Komajda M, Lam CS. Heart failure with preserved ejection fraction:a clinical dilemma[J]. Eur Heart J,2014,35(16):1022-1032.
[11] Guazzi M,VicenziM,Arena R,et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study[J]. Circulation,2011,124(2):164-174.
[12] Guazzi M,Gomberg MM,Arena R,et al. Pulmonary hypertension in heart failure with preserved ejection fraction[J]. J Heart Lung Transplant,2015,34(3):273-281.
[13] Anjan VY,Loftus TM,Burke MA,et al. Prevalence,clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction[J]. Am J Cardiol,2012,110(6):870-876.
[14] Lam CSP,Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction[J]. J Am Coll Cardiol, 2009,53(13):1119-1126.
[15] Leung CC, Moondra V,Catherwood E,et al. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction[J]. Am J Cardiol,2010,106(2):284-286.
[16] Shah AM, Claggett B,Sweitzer NK, et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction:findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist(TOPCAT)Trial[J]. Circ Heart Fail, 2014,7(5):740-751.
[17] Damy T,Goode KM,Kallvikbacka BA, et al. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure[J]. Eur Heart J, 2010,31(18):2280-2290.
[18] Thenappan T,Prins KW,Cogswell R,et al. Pulmonary hypertension secondary to heart failure with preserved ejection fraction[J]. Can J Cardiol,2015,31(4):430-439.
[19] Lam CS,Borlaug BA,Kane GC,et al. Age-associated increases in pulmonary artery systolic pressure in the general population[J]. Circulation,2009, 119(20):2663-2670.
[20] Bursi F, McNallan SM,Redfield MM,et al. Pulmonary pressures and death in heart failure[J]. J Am Coll Cardiol,2012,59(3):222-231.
[21] Tatebe S,Fukumoto Y,Sugimura K,et al. Clinical significance of reactive post-capillary pulmonary hypertension in patients with left heart disease[J]. Circ J, 2012,76(5):1235-1244.
[22] Agarwal R,Shah SJ,Foreman AJ,et al. Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction[J]. J Heart Lung Transplant, 2012,31(5):467-477.
[23] Thenappan T,Shah SJ,Gomberg MM, et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction[J]. Circ Heart Fail,2011,4(3):257-265.
[24] Robbins IM,Newman JH,Johnson RF,et al. Association of the metabolic syndrome with pulmonary venous hypertension[J]. Chest,2009,136(1):31-36.
[25] Maréchaux S, Neicu DV,Braun S, et al. Functional mitral regurgitation: a link to pulmonary hypertension in heart failure with preserved ejection fraction[J]. J Card Fail,2011,17(10):806-812.
[26] Miller WL,Mahoney DW,Michelena HI,et al. Contribution of ventricular diastolic dysfunction to pulmonary hypertension complicating chronic systolic heart failure[J]. JACC Cardiovasc Imaging,2011,4(9):946-954.
[27] Magne J,Lancellotti P,Pierard LA,et al. Exercise pulmonary hypertension in asymptomatic degenerative mitral regurgitation[J]. Circulation,2010,122(1):33-41.
[28] Gerges C,Gerges M,Lang MB,et al. Diastolic pulmonary vascular pressure gradient:a predictor of prognosis in “out-of-proportion” pulmonary hypertension[J]. Chest,2013,143(3):758-766.
[29] Tampakakis E, Leary PJ,Selby VN, et al. The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease[J]. JACC Heart Fail,2015,3(1):9-16.
[30] Mohammed SF, Hussain I,Abou EOF,et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study[J]. Circulation, 2014,130(25):2310-2320.
[31] Melenovsky V, Hwang SJ,Redfield MM,et al. Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction[J]. Circ Heart Fail,2015,8(2):295-303.
[32] Szwejkowski BR,Elder DH,Shearer F,et al. Pulmonary hypertension predicts all-cause mortality in patients with heart failure:a retrospective cohort study[J]. Eur J Heart Fail,2012,14(2):162-167.
[33] Kalogeropoulos AP,Siwamogsatham S,Hayek S,et al. Echocardiographic assessment of pulmonary artery systolic pressure and outcomes in ambulatory heart failure patients[J]. J Am Heart Assoc,2013,3(1):e000363.
相似文献/References:
[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(4):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(4):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[3]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(4):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[4]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(4):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[5]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(4):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[6]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(4):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[7]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(4):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
[8]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[9]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
[10]刘雪鸢 徐燕萍 殷跃辉.交感神经去除术在肺动脉高压治疗中的研究进展[J].心血管病学进展,2020,(5):480.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.010]
LIU Xueyuan,XU Yanping,YIN Yuehui.Sympathetic Denervation in Treatment of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(4):480.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.010]